

FUNCTIONAL UROLOGY WORKSHOP

ICS GUEST LECTURE

ADD-ON TO THE SOUTHERN BRAZILIAN CONGRESS OF UROLOGY

CURITIBA, BRAZIL, JUNE 23RD 2016

COORDINATOR: PROF. MARCIO AVERBECK (MEMBER OF ICS NEURO-UROLOGY
PROMOTION COMMITTEE)

Time	Activity	Date
1:00 - 1:10 pm	Opening MARCIO AVERBECK (Coordinator) ROGÉRIO DE FRAGA (SBU-PR Local Representative) Authorities: • <i>Marcio Carvalho (President of the South Brazilian Congress of Urology)</i> • <i>Dr. Fernando Meyer (President of SBU - section PR, President of Executive Commission – Southern Brazilian Congress of Urology)</i> • <i>Dr. Rodrigo Monerat (President of SBU - section SC)</i> • <i>Dra. Nanci Denicol (President of SBU - section RS)</i> • <i>Dr. Sebastião Westphal (Elected President of SBU – term 2018-19)</i> • <i>Dr. Archimedes Nardozza Jr. (President of SBU – term 2016-17)</i>	06/23/2016
1:10 - 1:50 pm	Module 1 FEMALE STRESS URINARY INCONTINENCE (SUI) Moderator: ALEXANDRE FORNARI 1:15-1:25: For: I do indicate single-incision sling Discussant: ROGÉRIO DE FRAGA (includes an educational video - 2 min – on the surgical technique) 1:25-1:35: Against: I don't indicate the single-incision sling (the conventional mid-urethral sling is better) Discussant: VIRGÍNIA MULLER 1:35-1:50: Replication, Rejoinder and Conclusions Replication - Duration: 3 min. ROGÉRIO DE FRAGA Rejoinder - Duration: 3 min. VIRGÍNIA MULLER Discussion and Conclusions - Duration: 9 min. ALEXANDRE FORNARI	06/23/2016

Aspects that will be discussed in the module: different models of single-incision slings, medium and long-term outcomes, possible complications, cost-effectiveness. Nowadays, is there still any indication for autologous sling?

Suggested references:

- Ford AA, Rogerson L, Cody JD, Ogah J. Mid-urethral sling operations for stress urinary incontinence in women. Cochrane Database Syst Rev. 2015 Jul 1;7:CD006375. doi: 10.1002/14651858.CD006375.pub3.
- Ford AA, Rogerson L, Cody JD, Ogah J. Mid-urethral sling operations for stress urinary incontinence in women. Cochrane Database Syst Rev. 2015 Jul 1;7:CD006375. doi: 10.1002/14651858.CD006375.pub3. Review.

Time	Activity	Date
13:50 - 14:30	Module 2 IDIOPATHIC OVERACTIVE BLADDER (OAB) Discussion of concept case Presenter: MARCIO AVERBECK <u>Aspects that will be discussed in the module:</u> criteria for the choice of antimuscarinics vs. beta-3 agonist, how to improve adherence to conservative treatment, how to define refractory OAB, third-line treatments. Discussant: SILVIO DE ALMEIDA Discussant: CRISTIANE CARBONI FORNARI Discussant: HELMUT MADERSBACHER Discussant: EMMANUEL CHARTIER KASTLER Discussant: JUAN CARLOS CASTAÑO	06/23/2016

Suggested references:

- Chapple CR, Kaplan SA, Mitcheson D, Blauwet MB, Huang M, Siddiqui E, Khullar V. Mirabegron 50 mg once-daily for the treatment of symptoms of overactive bladder: an overview of efficacy and tolerability over 12 weeks and 1 year. Int J Urol. 2014 Oct;21(10):960-7. doi: 10.1111/iju.12568. Epub 2014 Aug 4.
- Siegel S, Noblett K, Mangel J, Griebing TL, Sutherland SE, Bird ET, Comiter C, Culkun D, Bennett J, Zylstra S, Berg KC, Kan F, Irwin CP. Results of a prospective, randomized, multicenter study evaluating sacral neuromodulation with InterStim therapy compared to standard medical therapy at 6-months in subjects with mild symptoms of overactive bladder. Neurourol Urodyn. 2015 Mar;34(3):224-30. doi: 10.1002/nau.22544. Epub 2014 Jan 10.
- Olivera CK, Meriwether K, El-Nashar S, Grimes CL, Grace Chen CC, Orejuela F, Antosh D, Gleason J, Kim-Fine S, Wheeler T, McFadden B, Balk EM, Murphy M. Nonantimuscarinic treatment for overactive bladder: a systematic review. Am J Obstet Gynecol. 2016 Feb 4. pii: S0002-9378(16)00168-X. doi: 10.1016/j.ajog.2016.01.156.

Time	Activity	Date
2:30 - 5 pm	Module 3 NEUROGENIC LOWER URINARY TRACT DYSFUNCTION 2:30-2:35: Acknowledgement to the international societies that collaborated with the Voiding Dysfunctions Course/Southern Brazilian Urology Congress 2016 2:35-2:55: ICS Neuro-Urology Promotion Committee Guest Lecture: Management of detrusor overactivity in patients with spinal cord injury Speaker: EMMANUEL CHARTIER KASTLER	06/23/2016

	2:55-3:15: International Neuro-Urology Society (INUS) Guest Lecture: Management of detrusor underactivity in patients with neurological diseases – Is there any effective treatment? Speaker: HELMUT MADERSBACHER 3:15-3:35: State of the art lecture: Is there any indication for sacral neuromodulation (InterStim system implant) for patients with neurological diseases? Speaker: JUAN CARLOS CASTAÑO 3:35-3:40: Discussion 3:40-4:00: BREAK 4:00-4:30: BPH/LUTS IN PATIENTS WITH PARKINSON'S DISEASE Discussion of concept case Presenter: KARIN MARISE JAEGER ANZOLCH <u>Aspects that will be discussed in the module:</u> how can we know if lower urinary tract symptoms are (or are not) related to the neurological disease, urodynamic findings, antimuscarinics safety in patients with BPH-LUTS, potential benefits of mirabegron, when to indicate (and when not to indicate) TURP. Discussant: SEBASTIÃO WESTPHAL Discussant: NELSON BATEZINI Discussant: HELMUT MADERSBACHER Discussant: EMMANUEL CHARTIER KASTLER Discussant: LUIS SEABRA RIOS (Brazil)	
--	---	--

Suggested references:

- Sakakibara R, Panicker J, Finazzi-Agro E, Iacovelli V, Bruschini H; Parkinson's Disease Subcommittee, The Neurourology Promotion Committee in The International Continence Society. A guideline for the management of bladder dysfunction in Parkinson's disease and other gait disorders. *Neurourol Urodyn*. 2015 Mar 25. doi: 10.1002/nau.22764.
- Staskin DS1, Vardi Y, Siroky MB. Post-prostatectomy continence in the parkinsonian patient: the significance of poor voluntary sphincter control. *J Urol*. 1988 Jul;140(1):117-8.
- Zesiewicz TA, Evatt M, Vaughan CP, Jahan I, Singer C, Ordorica R, Salemi JL, Shaw JD, Sullivan KL; Non-Motor Working Group of the Parkinson Study Group (PSG). Randomized, controlled pilot trial of solifenacin succinate for overactive bladder in Parkinson's disease. *Parkinsonism Relat Disord*. 2015 May;21(5):514-20. doi: 10.1016/j.parkreldis.2015.02.025. Epub 2015 Mar 6.
- Murchison AG, Fletcher C, Cheeran B. Recurrence of dyskinesia as a side-effect of mirabegron in a patient with Parkinson's disease on DBS (GPI). *Parkinsonism Relat Disord*. 2016 Mar 16. pii: S1353-8020(16)30063-3. doi: 10.1016/j.parkreldis.2016.03.009. [Epub ahead of print]

Time	Activity	Date
2:30 – 5 pm	4:30-5:00: UROLOGICAL MANAGEMENT OF PATIENTS WITH SPINAL CORD INJURY Discussion of concept case Presenter: ROGÉRIO DE FRAGA <u>Aspects that will be discussed in the module:</u> strategies to prevent intermittent catheterization-related complications (conventional catheters vs. hydrophilic catheters), drug combinations to treat detrusor overactivity, botulinum toxin, indications for bladder augmentation.	06/23/2016

	Discussant: NEY FARIA NETO Discussant: GISELA ASSIS Discussant: HELMUT MADERSBACHER Discussant: EMMANUEL CHARTIER KASTLER Discussant: JUAN CARLOS CASTAÑO	
--	---	--

Suggested references:

- Utomo E, Groen J, Blok BF. Surgical management of functional bladder outlet obstruction in adults with neurogenic bladder dysfunction. Cochrane Database Syst Rev. 2014 May 24;5:CD004927. doi: 10.1002/14651858.CD004927.pub4. Review.
- MacDonald R, Fink HA, Huckabay C, Monga M, Wilt TJ. Botulinum toxin for treatment of urinary incontinence due to detrusor overactivity: a systematic review of effectiveness and adverse effects. Spinal Cord. 2007 Aug;45(8):535-41. Epub 2007 Apr 24. Review.

Time	Activity	Date
5:00 - 5:30	Module 4 POST-PROSTATECTOMY URINARY INCONTINENCE Discussion of concept case Presenter: MARCIO AVERBECK <u>Aspects that will be discussed in the module:</u> what is the best surgical technique (artificial urinary sphincter vs. slings), is there any indication for bulking agents (?), what is the best time to treat erectile dysfunction. Discussant: RODRIGO KETZER KREBS Discussant: GIOVANI PIONER Discussant: HELMUT MADERSBACHER Discussant: EMMANUEL CHARTIER KASTLER Discussant: CINTIA SPAGNOLO	06/23/2016

* A surgery video will be presented at the end (artificial urinary sphincter placement technique)

Suggested references:

- Mottet N, Boyer C, Chartier-Kastler E, Ben Naoum K, Richard F, Costa P. Artificial urinary sphincter AMS 800 for urinary incontinence after radical prostatectomy: the French experience. Urol Int. 1998;60 Suppl 2:25-9; discussion 35.
- Léon P, Chartier-Kastler E, Rouprêt M, Ambrogi V, Mozer P, Phé V. Long-term functional outcomes after artificial urinary sphincter implantation in men with stress urinary incontinence. BJU Int. 2015 Jun;115(6):951-7. doi: 10.1111/bju.12848. Epub 2014 Oct 23.
- Rehder P, Haab F, Cornu JN, Gozzi C, Bauer RM. Treatment of postprostatectomy male urinary incontinence with the transobturator retroluminal repositioning sling suspension: 3-year follow-up. Eur Urol. 2012 Jul;62(1):140-5. doi: 10.1016/j.eururo.2012.02.038. Epub 2012 Feb 25.

Time	Activity	Date
5:30 – 6:00	Module 5 PAINFUL BLADDER SYNDROME Discussion of concept case Presenter: CARLOS BELLUCCI <u>Aspects that will be discussed in the module:</u> <i>drug sequence, drug combination, bladder biopsy indication, hydrodistention, hyaluronic acid vs. DMSO, alternative treatments (botulinum toxin, sacral neuromodulation)</i> Discussant: KARIN ANZOLCH Discussant: ALEXANDRE FORNARI Discussant: CRISTIANE CARBONI FORNARI	06/23/2016

	Discussant: WALTAMIR HÜLSE Discussant: JUAN CARLOS CASTAÑO	
--	---	--

Suggested references:

- Chrysanthopoulou EL, Doumouchtsis SK. Challenges and current evidence on the management of bladder pain syndrome. *Neurourol Urodyn*. 2014 Nov;33(8):1193-201. doi: 10.1002/nau.22475. Epub 2013 Aug 14. Review.
- Peters KM, Jayabalan N, Bui D, Killinger K, Chancellor M, Tyagi P. Effect of Sacral Neuromodulation on Outcome Measures and Urine Chemokines in Interstitial Cystitis/Painful Bladder Syndrome Patients. *Low Urin Tract Symptoms*. 2015 May;7(2):77-83. doi: 10.1111/luts.12054. Epub 2014 Mar 17.
- Lamarre NS, Bjorling DE. Treatment of painful bladder syndrome/interstitial cystitis with botulinum toxin A: why isn't it effective in all patients? *Transl Androl Urol*. 2015 Oct;4(5):543-54. doi: 10.3978/j.issn.2223-4683.2015.10.02. Review.

Time	Activity	Date
6 – 6:05 pm	<u>Closing</u> MARCIO AVERBECK	06/23/2016